U
SCR

UBS’s SIMCERE PHARMACEUTICAL GROUP, ADS SCR Stock Holding History

UBS’s Portfolio SCR Stock Details SCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,248
Closed -$22K – 11444
2013
Q4 		$22K Buy
2,248
+999
+80% +$9.49K ﹤0.01% 8069
2013
Q3 		$12K Sell
1,249
-1,055
-46% -$9.99K ﹤0.01% 8686
2013
Q2 		$22K Buy
+2,304
New +$21.3K ﹤0.01% 7805

UBS's SCR Position: Q1 2014 in Review

UBS sold out of SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) in Q1 2014, closing a stake of 2,248 shares — an estimated $22K sold.

UBS first reported a position in SCR in Q2 2013 and held it in 3 quarters. The position peaked at $22K in Q4 2013. 0 funds tracked by Wall St. Rank hold SCR as of Q1 2014.

  • UBS reported no remaining SIMCERE PHARMACEUTICAL GROUP, ADS position as of Q1 2014 after selling out during the quarter.
  • UBS sold 2,248 SIMCERE PHARMACEUTICAL GROUP, ADS shares in Q1 2014, an estimated $22K.
  • UBS first reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS in Q2 2013 and held it in 3 quarters.
  • UBS's SIMCERE PHARMACEUTICAL GROUP, ADS position peaked at $22K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held SIMCERE PHARMACEUTICAL GROUP, ADS as of Q1 2014.

Based on UBS's 13F filing for Q1 2014, filed 15 May 2014.